Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.
Brief Summary: A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.


Options:
A: Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52 (Baseline and 52 Weeks); Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52 (Baseline and Week 52)
B: American college of Rheumatolofy (ACR)-20 responder rate at Week 24
C: Compare efficacy of two dose regimens of certolizumab pegol in combination with MTX to MTX alone in patients with RA measured by the ACR20 at week 24.
D: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169); Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ) at Day 365 (Day 365); Baseline and Mean Change From Baseline (BL) in Radiographic Erosion Score Results at Day 365 (BL (Day 0), Day 365); Participants With Deaths, Adverse Events (AEs) and SAEs in the Open-Label (OL) Period (Day 365 to Day 2,185); Participants With Hematology Values Meeting the Marked Abnormality Criteria in the OL Period (Day 365 to Day 2,185); Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria in the OL Period (Day 365 to Day 2,185); Participants With Electrolyte Values Meeting the Marked Abnormality Criteria in the OL Period (Day 365 to Day 2,185); Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting the Marked Abnormality Criteria in the OL Period (Day 365 to Day 2,185); Mean BL Immunoglobulins Over Time in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093); Mean Change From BL in Immunoglobulins in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093); Participants With Immunogenicity to Abatacept in the Cumulative DB + OL Period (Day 1 to Day 1,821); Number of Participants Experiencing Clinically Significant Changes in Vital Signs in the OL Period (Day 365 to Day 1,821. All changes in participant vital signs were monitored on each day of study drug administration prior to dosing and 60 minutes after dosing.); Number of Participants Experiencing AEs of Special Interest in the OL Period (Day 365 to Day 2,185); Mean BL Hematocrit in the OL Period (Baseline (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Participant Hematocrit in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Platelet Count in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Participant Platelet Count in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Hemoglobin, Total Protein, and Albumin in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Hemoglobin, Total Protein, and Albumin in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL White Blood Cells in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in White Blood Cells in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Liver Function Parameters in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Liver Function Parameters in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Select Laboratory Parameters in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Select Laboratory Parameters in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean BL Serum Electrolytes in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185); Mean Change From BL in Serum Electrolytes in the OL Period (BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185)

Answer: C